NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ARTV

Artiva Biotherapeutics Inc

Jul 11 • 04:00PM ET

2.04

Dollar change +0.25
Percentage change 13.97	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD REGN BMY AMGN MRNA PFE NVAX VRTX SAGE NTLA

| Held by: VTI VXF VTWO IBB VTWG IWC VTWV MSSM BIB IBBQ

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.98	Insider Own	49.52%	Shs Outstand	24.36M	Perf Week	26.71%
Market Cap	49.70M	Forward P/E	-	EPS next Y	-3.20	Insider Trans	0.00%	Shs Float	12.30M	Perf Month	-1.92%
Enterprise Value	-102.26M	PEG	-	EPS next Q	-0.81	Inst Own	63.60%	Short Float	5.28%	Perf Quarter	2.51%
Income	-71.72M	P/S	-	EPS this Y	43.44%	Inst Trans	-3.13%	Short Ratio	2.80	Perf Half Y	-80.72%
Sales	0.00M	P/B	0.29	EPS next Y	2.60%	ROA	-50.97%	Short Interest	0.65M	Perf YTD	-79.76%
Book/sh	6.93	P/C	0.30	EPS next 5Y	23.59%	ROE	-68.14%	52W High	17.31 -88.21%	Perf Year	-
Cash/sh	6.81	P/FCF	-	EPS past 3/5Y	12.99% -64.01%	ROIC	-40.05%	52W Low	1.47 38.78%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-49.95% -	Gross Margin	-	Volatility	7.93% 8.33%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	0.15	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	13.93	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	62.20	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	13.93	EPS Q/Q	-5.07%	SMA20	19.79%	Beta	2.16	Target Price	15.40
Payout	-	Debt/Eq	0.08	Sales Q/Q	-100.00%	SMA50	6.34%	Rel Volume	3.68	Prev Close	1.79
Employees	89	LT Debt/Eq	0.06	Earnings	May 08 BMO	SMA200	-69.08%	Avg Volume	232.55K	Price	2.04
IPO	Jul 19, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	-16.80% -	Trades		Volume	819,687	Change	13.97%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-11-25	Resumed	H.C. Wainwright	Buy	$12
Dec-30-24	Initiated	H.C. Wainwright	Buy	$20
Aug-13-24	Initiated	Wedbush	Outperform	$18
Aug-13-24	Initiated	TD Cowen	Buy
Aug-13-24	Initiated	Needham	Buy	$23
Aug-13-24	Initiated	Jefferies	Buy	$21
Aug-13-24	Initiated	Cantor Fitzgerald	Overweight	$23

May-28-25 04:05PM	Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire) +6.77%
May-13-25 04:05PM	Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting (GlobeNewswire) -11.71%
May-08-25 08:00AM	Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights (GlobeNewswire)
Apr-28-25 04:35PM	Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting (GlobeNewswire)
Apr-08-25 04:05PM	Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer (GlobeNewswire) -41.99%
04:05PM	Loading…
Mar-31-25 04:05PM	Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire) -5.06%
Mar-24-25 04:05PM	Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire) -8.43%
Feb-20-25 04:05PM	Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference (GlobeNewswire) -5.72%
Jan-29-25 04:05PM	Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D. (GlobeNewswire)
Nov-12-24 04:05PM	Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) -10.48%
Nov-11-24 04:05PM	Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-22-24 04:05PM	Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors (GlobeNewswire) +7.82%
Sep-10-24 04:05PM	Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Aug-29-24 04:05PM	Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-18-24 07:08PM	Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering (GlobeNewswire)

Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RA CAPITAL MANAGEMENT, L.P.	Director	Jul 22 '24	Buy	12.00	8,333,333	99,999,996	8,693,579	Jul 24 04:27 PM
5AM Partners VI, LLC	10% Owner	Jul 22 '24	Buy	12.00	833,333	9,999,996	1,182,054	Jul 24 04:15 PM
venBio Global Strategic Fund I	10% Owner	Jul 22 '24	Buy	12.00	416,666	4,999,992	1,936,637	Jul 22 08:26 PM
GC Corp.	10% Owner	Jul 22 '24	Buy	12.00	1,666,666	19,999,992	3,306,900	Jul 22 08:25 PM
GC Corp.	10% Owner	Jul 22 '24	Buy	12.00	416,666	4,999,992	1,260,512	Jul 22 08:25 PM
Huh Yong-Jun	Director	Jul 22 '24	Buy	12.00	2,083,332	24,999,984	3,306,900	Jul 22 08:22 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARTV

Artiva Biotherapeutics Inc

Upgrade your FINVIZ experience